person · Reporting owner

Gayko Urte

Disclosed activity across 1 company

Tapewire entity: 127811
SEC CIK: 0001559217

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Summit Therapeutics Inc.SMMT · Entity 3477	Director	April 25, 2022	April 26, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Summit Therapeutics Inc.

Report date April 25, 2022 · Filed April 26, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2032-04-25	Direct	400,000	Reported balance After 2022-04-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-04-25 · Grant · Acquired 400,000 · Balance 400,000 F2: Not applicable. F1: The option was granted on April 25, 2022. The shares underlying the option are scheduled to vest in four equal annual installments over four years.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on April 25, 2022. The shares underlying the option are scheduled to vest in four equal annual installments over four years.

F2: Not applicable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 25, 2022 Filed Apr 26, 2022 16:36 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	400,000	Not disclosed Strike: $1.93	Not disclosed	Disclosure SEC source: 0001599298-22-000034 · wf-form4_165100539719830.xml · derivative · entry 1 Gayko Urte · CIK 0001559217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-04-25 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on April 25, 2022. The shares underlying the option are scheduled to vest in four equal annual installments over four years. Read SEC document
January 03, 2022 Filed Jan 5, 2022 16:07 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	42,553	$1.13 Strike: $2.82	$48,084.89	Disclosure SEC source: 0001599298-22-000008 · wf-form4_164141681907145.xml · derivative · entry 2 Gayko Urte · CIK 0001559217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,553 Underlying: Common Stock · 42,553 shares Expires 2032-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $48,000. F3 · derivative.exercise_date: The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document
January 03, 2022 Filed Jan 5, 2022 16:07 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	25,000	Not disclosed Strike: $2.82	Not disclosed	Disclosure SEC source: 0001599298-22-000008 · wf-form4_164141681907145.xml · derivative · entry 1 Gayko Urte · CIK 0001559217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document
November 03, 2021 Filed Nov 16, 2021 17:17 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	4,041	Not disclosed Strike: $5.54	Not disclosed	Disclosure SEC source: 0000921895-21-002700 · form412566001_11162021.xml · derivative · entry 2 Gayko Urte · CIK 0001559217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,041 Underlying: Common Stock · 4,041 shares Expires 2031-11-03 F3 · price: Not applicable. F2 · derivative.exercise_date: The option was granted on November 3, 2021 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document
November 03, 2021 Filed Nov 16, 2021 17:17 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	200,000	Not disclosed Strike: $5.54	Not disclosed	Disclosure SEC source: 0000921895-21-002700 · form412566001_11162021.xml · derivative · entry 1 Gayko Urte · CIK 0001559217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-11-03 F3 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on November 3, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 3, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.